QUEBEC CITY, Feb. 21 /CNW Telbec/ - Biopharmacopae Design International
Inc. ("Biopharmacopae"), a company specialized in the discovery and
development of innovative, science-based, plant-derived ingredients and
products for the nutraceutical and cosmeceutical industries, announced
today that it has closed a $2 Million private financing round with
Canadian venture capital firm Avrio Ventures. This second round of
financing from Avrio Ventures confirms the company's growth potential.
The funds will contribute to further advance the commercialization of
Biopharmacopae's flagship product RIDOVIR™ Cold and its other
discoveries in the Canadian and International markets.
Biopharmacopae recently launched RIDOVIR™ Cold, a new cough and cold
natural health product in several Canadian pharmacies. In addition, the
company joined forces with well-known pharmacist and health expert
Jean-Yves Dionne. The company is currently expanding its presence in
the market by establishing additional commercial agreements with other
pharmacies and large retail stores. "Biopharmacopae holds a portfolio
of extremely promising products with significant market potential, and
their recent studies on the antiviral activity of their cough and cold
natural health product, RIDOVIR™ Cold, are very encouraging, says Mr.
Aki Georgacacos, Partner at Avrio Ventures. In addition, with the
company's expertise and recent discovery, Biopharmacopae is
well-positioned within the industry to become a strategic partner for
companies looking for innovative products with great market potential."
"We have created a technology platform adapted to the discovery of new
health benefits related to plants and this gives us a competitive
advantage when it comes to developing innovative health and beauty
solutions" explains Dr. Johane Guay, Ph.D., Biopharmacopae's President
and CEO. Dr. Guay stated that she is extremely grateful for Avrio's
financial support and business and industry-related knowledge. "The
solidity of our partnership with Avrio as well as their expertise and
support are great assets to the existing strengths of the company.
Together, we are currently pursuing further clinical research studies
and intensifying our commercial efforts for RIDOVIR™ Cold in Canada and
on the export markets."
Biopharmacopae is a Canadian company known for the superior quality of
its innovative plant-derived active ingredients and products. These
products and ingredients are distributed through a worldwide network of
partners recognized in the cosmetic and natural health product markets.
The company develops and manufactures its products and active
ingredients using a rigorous pharmaceutical approach that
scientifically demonstrates their safety and efficacy. The company
distinguishes itself with its original collection of over 15,000 plant
extracts and with its exclusive technology platform, eXcelerate that
allows for the rapid screening of thousands of plant extracts,
highlighting their specific beneficial effects on human health.
Biopharmacopae contributes to the advancement of science and
improvement of the quality of life by developing natural products and
ingredients that combine tradition and innovation.
About Avrio Ventures Management Corporation
Avrio Ventures provides Canada's promising industrial bioproducts,
nutraceutical ingredients and food technology companies with the
investment support and resources they need to succeed. With a
collective 80 years of experience in Canada's industrial life science
venture capital sector through the successes of FCC Ventures, a
division of Farm Credit Canada, and Kirchner Investment Management
Corporation, the Avrio team is well equipped with deep, sector-specific
knowledge. Also providing strategic guidance, operational skills and
access to industry relationship's the Avrio team is uniquely qualified
to support an entrepreneurial industrial life sciences organization
throughout its growth.
About Mr Jean-Yves Dionne
Jean-Yves Dionne is a pharmacist, a scientific advisor and consultant in
the natural health product (NHP) industry for several companies and
professional groups. His research focuses on the interaction between
NHPs and drugs as well as on conventional medicine and complementary or
alternative medicine. He is the author or co-author of several books,
including "Herbs, Everyday Reference for Health Professionals".
For further information:
Lyne Dubois, MBA, Sales and Marketing Director
Biopharmacopae Design International Inc.
Aki Georgacacos, Partner
Isabelle Saillant, Parenthèses Communications
Tel.: 418 527-4537; email@example.com
Tel.: 514 733-4779; firstname.lastname@example.org